Highline Wealth Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$43.2K Buy
303
+50
+20% +$7.58K 0.01% 278
2026
Q2
$39.6K Sell
253
-10
-4% -$1.5K 0.01% 266
2026
Q1
$40.2K Hold
263
– – 0.01% 192
2025
Q4
$36.3K Buy
263
+5
+2% +$655 0.01% 166
2025
Q3
$33.1K Sell
258
-32
-11% -$3.9K 0.01% 194
2025
Q2
$35.1K Buy
290
+131
+82% +$14.8K 0.01% 165
2025
Q1
$17.7K Buy
159
+93
+141% +$9.9K 0.01% 221
2024
Q4
$6.42K Sell
66
-73
-53% -$7.78K ﹤0.01% 301
2024
Q3
$16K Buy
139
+26
+23% +$2.95K 0.01% 207
2024
Q2
$12K Buy
113
+87
+335% +$8.73K ﹤0.01% 204
2024
Q1
$2.52K Hold
26
– – ﹤0.01% 315
2023
Q4
$2.62K Buy
26
+20
+333% +$1.93K ﹤0.01% 283
2023
Q3
$611 Hold
6
– – ﹤0.01% 337
2023
Q2
$605 Hold
6
– – ﹤0.01% 296
2023
Q1
$552 Hold
6
– – ﹤0.01% 302
2022
Q4
$544 Hold
6
– – ﹤0.01% 300
2022
Q3
$456 Buy
+6
New +$497 ﹤0.01% 301

Other funds holding NVS

Highline Wealth Partners's NVS Position: Q3 2026 in Review

Highline Wealth Partners increased its Novartis (NVS) stake by 20% in Q3 2026, buying an estimated $7.58K and bringing the position to 303 shares worth $43.2K. The position accounts for 0.01% of the portfolio, ranked #278.

Highline Wealth Partners first reported a position in NVS in Q3 2022 and has held it in 17 quarters since. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Highline Wealth Partners held 303 shares of Novartis worth $43.2K as of Q3 2026.
  • Highline Wealth Partners bought 50 Novartis shares in Q3 2026, an estimated $7.58K.
  • Novartis made up 0.01% of Highline Wealth Partners's portfolio in Q3 2026, its #278 holding.
  • Highline Wealth Partners first reported a position in Novartis in Q3 2022 and has held it in 17 quarters since.
  • 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.